523 related articles for article (PubMed ID: 10398297)
21. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism.
Arai N; Misugi K; Goshima Y; Misu Y
Brain Res; 1990 May; 515(1-2):57-63. PubMed ID: 2357577
[TBL] [Abstract][Full Text] [Related]
22. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism.
Duan W; Zhu X; Ladenheim B; Yu QS; Guo Z; Oyler J; Cutler RG; Cadet JL; Greig NH; Mattson MP
Ann Neurol; 2002 Nov; 52(5):597-606. PubMed ID: 12402257
[TBL] [Abstract][Full Text] [Related]
23. Selegiline can mediate neuronal rescue rather than neuronal protection.
Tatton WG
Mov Disord; 1993; 8 Suppl 1():S20-30. PubMed ID: 8302304
[TBL] [Abstract][Full Text] [Related]
24. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus.
Hamre K; Tharp R; Poon K; Xiong X; Smeyne RJ
Brain Res; 1999 May; 828(1-2):91-103. PubMed ID: 10320728
[TBL] [Abstract][Full Text] [Related]
25. Animal models of Parkinson's disease in rodents induced by toxins: an update.
Hirsch EC; Höglinger G; Rousselet E; Breidert T; Parain K; Feger J; Ruberg M; Prigent A; Cohen-Salmon C; Launay JM
J Neural Transm Suppl; 2003; (65):89-100. PubMed ID: 12946051
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Iwashita A; Yamazaki S; Mihara K; Hattori K; Yamamoto H; Ishida J; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Jun; 309(3):1067-78. PubMed ID: 14985416
[TBL] [Abstract][Full Text] [Related]
27. Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.
Cheng FC; Ni DR; Wu MC; Kuo JS; Chia LG
Neurosci Lett; 1998 Aug; 252(2):87-90. PubMed ID: 9756328
[TBL] [Abstract][Full Text] [Related]
28. Ultrastructural changes in substantia nigra and striatum observed on a mouse model of Parkinson's disease induced by MPTP administration.
Lewandowska E; Kurkowska-Jastrzebska I; Lechowicz W; Członkowska A; Członkowski A
Folia Neuropathol; 1999; 37(4):239-42. PubMed ID: 10705644
[TBL] [Abstract][Full Text] [Related]
29. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.
Hantraye P; Varastet M; Peschanski M; Riche D; Cesaro P; Willer JC; Maziere M
Neuroscience; 1993 Mar; 53(1):169-78. PubMed ID: 8469305
[TBL] [Abstract][Full Text] [Related]
30. MPTP as a mitochondrial neurotoxic model of Parkinson's disease.
Przedborski S; Tieu K; Perier C; Vila M
J Bioenerg Biomembr; 2004 Aug; 36(4):375-9. PubMed ID: 15377875
[TBL] [Abstract][Full Text] [Related]
31. Dopamine in the extrapyramidal motor function. A study based upon the MPTP-induced primate model of parkinsonism.
Chiueh CC
Ann N Y Acad Sci; 1988; 515():226-38. PubMed ID: 3259118
[No Abstract] [Full Text] [Related]
32. Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra.
Miller RM; Callahan LM; Casaceli C; Chen L; Kiser GL; Chui B; Kaysser-Kranich TM; Sendera TJ; Palaniappan C; Federoff HJ
J Neurosci; 2004 Aug; 24(34):7445-54. PubMed ID: 15329391
[TBL] [Abstract][Full Text] [Related]
33. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.
Gerlach M; Riederer P
J Neural Transm (Vienna); 1996; 103(8-9):987-1041. PubMed ID: 9013391
[TBL] [Abstract][Full Text] [Related]
34. Immunological changes in the MPTP-induced Parkinson's disease mouse model.
Bieganowska K; Członkowska A; Bidziński A; Mierzewska H; Korlak J
J Neuroimmunol; 1993 Jan; 42(1):33-7. PubMed ID: 8423206
[TBL] [Abstract][Full Text] [Related]
35. MPTP-Parkinsonism is accompanied by persistent expression of a delta-FosB-like protein in dopaminergic pathways.
Pérez-Otaño I; Mandelzys A; Morgan JI
Brain Res Mol Brain Res; 1998 Jan; 53(1-2):41-52. PubMed ID: 9473580
[TBL] [Abstract][Full Text] [Related]
36. TorsinA, the gene linked to early-onset dystonia, is upregulated by the dopaminergic toxin MPTP in mice.
Kuner R; Teismann P; Trutzel A; Naim J; Richter A; Schmidt N; Bach A; Ferger B; Schneider A
Neurosci Lett; 2004 Jan; 355(1-2):126-30. PubMed ID: 14729251
[TBL] [Abstract][Full Text] [Related]
37. A guide to neurotoxic animal models of Parkinson's disease.
Tieu K
Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a009316. PubMed ID: 22229125
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence.
Obinu MC; Reibaud M; Blanchard V; Moussaoui S; Imperato A
Mov Disord; 2002 Jan; 17(1):13-9. PubMed ID: 11835434
[TBL] [Abstract][Full Text] [Related]
39. Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells.
Wang X; Qin ZH; Leng Y; Wang Y; Jin X; Chase TN; Bennett MC
J Neurochem; 2002 Dec; 83(5):1094-102. PubMed ID: 12437580
[TBL] [Abstract][Full Text] [Related]
40. Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease?
Poirier J; Thiffault C
Eur Neurol; 1993; 33 Suppl 1():38-43. PubMed ID: 8375431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
